Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis
- 1 May 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 18 (5), 803-808
- https://doi.org/10.1002/ibd.21853
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitisThe Esophagus, 2010
- Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patientsThe Esophagus, 2010
- A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitisGut, 2006
- Tacrolimus Is Safe and Effective in Patients with Severe Steroid-Refractory or Steroid-Dependent Inflammatory Bowel Disease-A Long-Term Follow-UpThe American Journal of Gastroenterology, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2005
- Effect of oral tacrolimus (FK 506) on steroid‐refractory moderate/severe ulcerative colitisAlimentary Pharmacology & Therapeutics, 2003
- Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2003
- Response of Refractory Colitis to Intravenous or Oral Tacrolimus (FK506)Inflammatory Bowel Diseases, 2002
- Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506)The American Journal of Gastroenterology, 1998
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisThe New England Journal of Medicine, 1987